Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2016', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome) - The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects - The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Interstitial Cystitis (Painful Bladder Syndrome) Overview 8 Therapeutics Development 9 Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 9 Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 10 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 11 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 12 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 16 Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 17 Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 18 Afferent Pharmaceuticals, Inc. 18 Allergan Plc 19 Aquinox Pharmaceuticals Inc. 20 Astellas Pharma Inc. 21 Kytogenics Pharmaceuticals, Inc. 22 Lipella Pharmaceuticals, Inc. 23 MediPost Co., Ltd. 24 Qu Biologics Inc. 25 UCB S.A. 26 Urigen Pharmaceuticals, Inc. 27 UroGen Pharmaceuticals, Ltd. 28 Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 29 Assessment by Monotherapy Products 29 Assessment by Combination Products 30 Assessment by Target 31 Assessment by Mechanism of Action 33 Assessment by Route of Administration 35 Assessment by Molecule Type 37 Drug Profiles 39 (heparin + lidocaine) - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 AF-219 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 AQX-1125 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ASP-6294 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Cartistem - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 certolizumab pegol - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 GM-0111 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 lidocaine hydrochloride - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 LP-08 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 mesalamine - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 NEO-5024 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 NEO-5937 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 onabotulinumtoxin A - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 onabotulinumtoxinA SR - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 pentosan polysulfate sodium - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 QBECP-SSI - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates 76 Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 90 Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 91 Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 92 Featured News & Press Releases 92 Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA 92 Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration 93 Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 93 Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis 94 Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 94 Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results from Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 95 Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 96 Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 96 May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 96 Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 98 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 99 Disclaimer 100
List of Tables
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H1 2016 9 Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H1 2016 10 Number of Products under Development by Companies, H1 2016 11 Number of Products under Investigation by Universities/Institutes, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 13 Comparative Analysis by Clinical Stage Development, H1 2016 14 Comparative Analysis by Early Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Investigation by Universities/Institutes, H1 2016 17 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H1 2016 18 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H1 2016 19 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H1 2016 20 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H1 2016 21 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H1 2016 22 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H1 2016 23 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H1 2016 24 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H1 2016 25 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H1 2016 26 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H1 2016 27 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H1 2016 28 Assessment by Monotherapy Products, H1 2016 29 Assessment by Combination Products, H1 2016 30 Number of Products by Stage and Target, H1 2016 32 Number of Products by Stage and Mechanism of Action, H1 2016 34 Number of Products by Stage and Route of Administration, H1 2016 36 Number of Products by Stage and Molecule Type, H1 2016 38 Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H1 2016 76 Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H1 2016 90 Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H1 2016 91
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
